Reported about 12 hours ago
Sanofi plans to repurchase €5 billion ($5.2 billion) of its shares and expects to increase profits at a faster rate this year, shifting its focus from consumer health to high-growth pharmaceuticals like its RSV vaccine. The drugmaker foresees a low double-digit rise in earnings per share in 2025, following a deal to divest its consumer health business. While sales are expected to grow, the company also faces competition in the RSV space and is keen on dialogue with the new U.S. administration regarding healthcare access.
Source: YAHOO